President Trump Launches TrumpRx.gov to Lower Drug Prices for Americans
Impact Score: 3.8
Timeline: Initiative launched on February 5, 2026, following phased executive actions starting May 12, 2025
Summary: TrumpRx.gov was launched to offer significant discounts on costly prescription drugs by aligning U.S. prices with most-favored-nation (MFN) rates from developed countries. Initial drug deals involve major manufacturers and cover 40 high-cost drugs including diabetes, obesity, fertility, and respiratory treatments. The program aims to reduce patient out-of-pocket costs, address price transparency, and prevent subsidization of U.S. drug prices by higher global rates. Key risks include operational, clinical trial, revenue, and supply chain impacts for Vanderbilt University Medical Center and affiliated programs.
Key Actions: Monitor program developments, assess clinical and pharmacy impacts, engage in health policy research, advocate for continued drug price reforms, and explore research and educational opportunities tied to new pricing models.
View Full Report
